AbbVie (NYSE:ABBV) Issues Q3 2025 Earnings Guidance

AbbVie (NYSE:ABBV) updated its third quarter 2025 earnings guidance on Friday. The company provided EPS guidance of 1.740-1.780 for the period, compared to the consensus EPS estimate of 3.260. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 10.380-10.580 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Saturday, September 27th. Guggenheim boosted their price target on AbbVie from $216.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Cantor Fitzgerald increased their price objective on AbbVie from $215.00 to $245.00 and gave the stock an “overweight” rating in a research report on Monday, September 15th. Wells Fargo & Company lifted their target price on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Evercore ISI upped their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Four analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $228.22.

AbbVie Stock Down 1.1%

Shares of NYSE ABBV opened at $234.07 on Friday. The stock has a market capitalization of $413.49 billion, a P/E ratio of 111.46, a PEG ratio of 1.37 and a beta of 0.51. The stock’s fifty day moving average is $210.77 and its 200 day moving average is $195.90. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. During the same period in the prior year, the company earned $2.65 EPS. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Sell-side analysts forecast that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, October 15th. AbbVie’s dividend payout ratio (DPR) is 312.38%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of the firm’s stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president owned 58,247 shares of the company’s stock, valued at approximately $11,562,611.97. This trade represents a 18.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The disclosure for this sale can be found here. 0.25% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC lifted its holdings in shares of AbbVie by 234.0% in the second quarter. Headlands Technologies LLC now owns 8,812 shares of the company’s stock worth $1,636,000 after acquiring an additional 6,174 shares during the last quarter. Nikulski Financial Inc. increased its position in AbbVie by 2.0% during the 2nd quarter. Nikulski Financial Inc. now owns 39,671 shares of the company’s stock worth $7,364,000 after purchasing an additional 775 shares in the last quarter. Security National Bank of Sioux City Iowa IA lifted its stake in AbbVie by 14.5% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 15,337 shares of the company’s stock valued at $2,847,000 after purchasing an additional 1,948 shares during the last quarter. MUFG Securities EMEA plc acquired a new stake in AbbVie in the second quarter valued at approximately $969,000. Finally, Brooks Moore & Associates Inc. grew its stake in shares of AbbVie by 0.5% during the second quarter. Brooks Moore & Associates Inc. now owns 28,492 shares of the company’s stock worth $5,386,000 after buying an additional 149 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.